3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other hematologic neoplasm
1
Gastrointestinal
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
9
Lung Neoplasms
4
Neoplasms
3
Sarcoma
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Hematologic Neoplasms
2
Adenocarcinoma of Lung
2
Stomach Neoplasms
1
Neuroblastoma
1
Neoplasm Metastasis
1
Lymphoproliferative Disorders
1
Glioma
1
EGFR-mutant Non-small Cell Lung Cancer
1
Carcinoma
1
Bronchial Neoplasms
1
Interventions
Temozolomide
42
Magnetic Resonance Spectroscopy
41
Radiotherapy
22
Specimen Handling
18
Biopsy
13
X-Rays
10
Radiation
10
trametinib
8
Bevacizumab
8
Nivolumab
7
Blood Specimen Collection
7
olaparib
6
fluorodopa F 18
6
dabrafenib
6
Radiotherapy, Intensity-Modulated
6
Phantoms, Imaging
6
Nuclear Medicine Department, Hospital
6
Lomustine
6
pembrolizumab
5
abemaciclib
5
Standard of Care
5
vorasidenib
4
ulixertinib
4
larotrectinib
4
ivosidenib
4
erdafitinib
4
Surgical Procedures, Operative
4
Dianhydrogalactitol
4
Cyclophosphamide
4
Aminolevulinic Acid
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Glioma
×
capmatinib
×
1 year
×
Clear all
NCT06988475
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled